The era of in vivo T cell engineering

Ramos GC, Hudecek M (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Med Cell Press

Book Volume: 3

Pages Range: 85-86

Journal Issue: 2

DOI: 10.1016/j.medj.2022.01.012

Abstract

Cell therapy with genetically engineered T cells has revolutionized the treatment of malignant diseases, but its potential use beyond the realms of oncology has been underexplored. In a recent study, Rurik et al.1 built on the technologies underlying mRNA vaccines to transduce T cells in vivo, harnessing them to target cardiac fibrosis.

Involved external institutions

Universitätsklinikum Würzburg DE Germany (DE)

How to cite

APA:

Ramos, G.C., & Hudecek, M. (2022). The era of in vivo T cell engineering. Med, 3(2), 85-86. https://doi.org/10.1016/j.medj.2022.01.012

MLA:

Ramos, Gustavo Campos, and Michael Hudecek. "The era of in vivo T cell engineering." Med 3.2 (2022): 85-86.

BibTeX: Download